Roche
The pharma giant’s AI factory combines on-premises and cloud GPU infrastructure, leveraging more than 3,500 Blackwell GPUs for AI-driven drug discovery and research.
At HIMSS26, panelists said the OR is a "black box" evolving into a connected ecosystem, with surgical video and procedural data providing new ways to prevent complications.
The partnership will expedite the availability of Freenome's tests in markets outside the U.S, according to the company.
Also, Neurophet will tap into Roche's data to further improve its brain scan analysis AI.
Also, Japan has approved iRhythm's AI-based continuous ECG monitoring system.
Also, a startup in India has received seed funding to expand further its VR-based mental health DTx.
The pharma giant will integrate more than 20 AI algorithms from eight collaborators into its navify Digital Pathology enterprise software to help improve pathology workflows.
The partnership aims to raise patient safety, boost cost-effectiveness and improve care by combining Glytec's software with Roche's system.
The pharma giant will also pay $55 million to fund the point-of-care diagnostics platform until the acquisition closes, which is expected to occur by mid-2024.
Roche will leverage PicnicHealth's real-world datasets for Alzheimer’s Disease, Alzheimer’s Disease-related dementia and myasthenia gravis.